11 results about "Rhodococcus erythropolis" patented technology

The present invention belongs to the field of biomedicine, and specifically relates to an antimicrobial peptide derived from lactoferrin and its application. The antimicrobial peptide derived from lactoferrin, whose amino acid sequence is shown in any one of SEQ ID NOs: 1 to 98, has a broad-spectrum antimicrobial effect, especially significant antibacterial effect against Pseudomonas putida, Rhodococcus erythropolis, Bacillus subtilis, Malassezia furfur, Cryptococcus neoformans, and Candida albicans, and has great application value.

The invention belongs to the technical field of symbiotic colonization of microorganisms and plants, and particularly relates to a fungicide for relieving phosphorus starvation of rice as well as a preparation method and application of the fungicide, including fungus mortierella which can effectively adapt to a soil flooding environment and is slightly influenced by anaerobic environments such as water logging when symbiotic colonization occurs between the mortierella and rice; on the basis, a bacterial mixed group of rhodococcus erythropolis and pseudomonas aeruginosa is further introduced, acid-aluminum stress of rice rhizosphere can be effectively reduced, stiffness of root tip cell walls is relieved, symbiotic colonization of mortierella to rice is further promoted, abundance of mortierella in rice rhizosphere soil is improved, and rice yield is increased. Therefore, the utilization capability of the rice on phosphorus nutrients is improved.

The invention discloses a biological catalytic synthesis method of chiral 2-amino-1-methylenepropanamide and an enzyme catalyst of the chiral 2-amino-1-methylenepropanamide. According to the present invention, one or more key amino acids in the amide hydrolase derived from Rhodococcus erythropolis AJ270 are subjected to mutation to obtain the mutant, the mutant has characteristics of high or reverse enantioselectivity when the hydrolysis reaction of the racemization 2-substituted-2-amino-1-methylene propanamide substrate is catalyzed, and the chiral compound is obtained with the high ee value; and an enantiomer of a wild type amide hydrolase catalytic product can be obtained. A method for preparing chiral 2-substituted-2-amino-1-methylene propanamide by using the mutant through biological catalysis has the characteristics of simplicity and convenience in operation, high reaction efficiency, mild reaction conditions, high enantioselectivity, easiness in product separation and high product purity, and has a very good application prospect.

The invention belongs to the technical field of chemical engineering, and particularly relates to a bromine separation and purification method which comprises the following steps: mixing rhodococcus erythropolis and bacillus cereus, and inoculating a culture medium with the mixture to prepare a bacterial suspension; adding the bacterial suspension into the bromine-containing wastewater in proportion, performing multi-stage filtration on the bromine-containing wastewater subjected to biological treatment, and performing electrodialysis concentration to obtain a concentrated solution; transferring the concentrated solution to a reaction kettle, adding a catalyst and a trapping agent, and dynamically introducing liquid-phase ozone in a gradient manner to obtain an oxidized solution; the oxidation liquid is pumped into a gas stripping tower for gas stripping, and generated bromine vapor is introduced into an adsorption tower and adsorbed by filler in the adsorption tower; and transferring the filler to a desorption tank, condensing bromine vapor generated in the desorption process, feeding the condensed bromine vapor into a trapping tank, and condensing and collecting the condensed bromine vapor to obtain high-purity liquid bromine. The method solves the problems of chlorine escape risk, organic solvent residue, low bromine yield and the like in the prior art.

This invention discloses a microbial agent for regulating the microecology of aquatic bodies and its preparation method. The method includes: inoculating Rhodococcus erythropolis into a liquid culture medium, activating and expanding the culture at 28°C to obtain a Rhodococcus erythropolis fermentation broth with an effective viable count of 2.0×10⁹–2.8×10⁹ CFU / mL; then subjecting the broth to stepwise low-temperature adaptation at 15°C, 10°C, and 5°C to obtain a low-temperature adapted Rhodococcus erythropolis bacterial solution; culturing Bacillus glacialis and Bacillus belesii at 37°C and mixing them at a viable count ratio of 1:1 to obtain a Bacillus bacterial solution; subsequently, compounding the low-temperature adapted Rhodococcus erythropolis bacterial solution and the Bacillus bacterial solution at a viable count ratio of 1:(0.5–4), adding survival protection components and dispersion stabilizing components, and mixing thoroughly to obtain the microbial agent.

This invention relates to the field of biomedical detection technology, specifically to plasma circulating microbial biomarkers for early screening of gastric cancer and their applications. The plasma circulating microbial biomarkers include: *Ralstonia solanacearum*, *Staphylococcus aureus*, *Alternaria metachromatica*, *Porphyromonas gingivalis*, *Lactobacillus reuteri*, *Rhodococcus erythropolis*, *Akkermansia muciniphila*, *Lactobacillus gasseri*, *Bifidobacterium bifidum*, and *Neisseria gonorrhoeae*. This invention screens and, for the first time, combines 10 specific microbial biomarkers with Low Pass technology. WGS technology can achieve detection results at low depths, significantly reducing screening costs while ensuring detection sensitivity, and providing a brand-new solution for early gastric cancer screening.

The present invention belongs to the field of chemical technology and specifically relates to a method for separating and purifying bromine, comprising the following steps: mixing Rhodococcus erythropolis and Bacillus cereus, inoculating the mixture into a culture medium, and preparing a bacterial suspension; adding the bacterial suspension to bromine-containing wastewater in proportion, subjecting the biologically treated bromine-containing wastewater to multi-stage filtration and electrodialysis concentration to obtain a concentrated solution; transferring the concentrated solution to a reactor, adding a catalyst and a capture agent, and dynamically introducing liquid ozone to obtain an oxidized solution; pumping the oxidized solution into a stripping tower for stripping, and the generated bromine vapor is introduced into an adsorption tower and adsorbed by the packing inside the adsorption tower; transferring the packing to a desorption tank, and the bromine vapor generated during the desorption process is condensed and then enters a capture tank, where it is collected by condensation to obtain high-purity liquid bromine. This method solves the problems of chlorine gas escape risk, residual organic solvents, and low bromine yield in the prior art.

The invention belongs to the technical field of biological catalysis, and particularly relates to a method for catalyzing hydrolysis of oxetane by using a series of epoxy hydrolase. According to the method, epoxy hydrolase in 23 databases is mined and represented through the technologies of gene mining, heterologous expression and the like, and it is determined that epoxy hydrolase and the like from metagenome DNA (Deoxyribonucleic Acid), Rhodococcus erythropolis, Rhodococcus subtilis, Actinomadura namibiensis and Rhodococcus aureus are adopted as catalytic enzymes, and the catalytic enzymes are used for catalyzing 2-phenyl oxetane to generate (S)-1-phenyl-1, 3-propylene glycol, so that the 2-phenyl oxetane can be used for catalyzing 2-phenyl oxetane to generate (S)-1-phenyl-1, 3-propylene glycol, and the application of the 2-phenyl oxetane to prepare the (S)-1-phenyl-1, 3-propylene glycol and the application of the 2-phenyl oxetane to prepare the (S)-1, 3-propylene glycol.

The invention relates to the technical field of biomedical detection, in particular to a plasma circulating microbial marker for early screening of gastric cancer and application of the plasma circulating microbial marker. The plasma circulating microbial marker comprises the following components: Ralstonia solanacearum, Staphylococcus aureus, Alternaria mellea, Porphyromonas gingivalis, Lactobacillus reuteri, Rhodococcus erythropolis, Ackermania muciniphila, Lactobacillus gasseri, and Bifidobacterium bifidum, and the plasma circulating microbial marker comprises the following components: Ralstonia solanacearum, Staphylococcus aureus, Alternaria mellea, Porphyromonas gingivalis, Lactobacillus reuteri, Rhodococcus erythropolis, Ackermania muciniphila, Lactobacillus gasseri, and Bifidobacterium bifidum. The detection effect can be achieved under the condition of low depth, the screening cost is greatly reduced while the detection sensitivity is ensured, and a brand new solution is provided for early screening of gastric cancer.

The present application provides a kind of derived from Rhodococcus erythropolis L-pantoic acid lactone dehydrogenase of (Rhodococcus erythropolis) and its mutant, nucleic acid molecule for encoding the L-pantoic acid lactone dehydrogenase or its mutant, vector for expressing the L-pantoic acid lactone dehydrogenase or its mutant in host cell and the engineering bacteria of expression the enzyme or its mutant.The present application further provides a kind of co-expression the L-pantoic acid lactone dehydrogenase or its mutant and any one or more selected from the following group: molecular chaperone, D-ketopantoate reductase and glucose dehydrogenase.The present application further provides a kind of D-pantoic acid lactone production method, which uses the engineering bacteria of expression the L-pantoic acid lactone dehydrogenase or its mutant derived from Rhodococcus erythropolis .

The present application provides a L-pantoic acid lactone dehydrogenase derived from Rhodococcus erythropolis, and a mutant thereof, a nucleic acid molecule encoding the L-pantoic acid lactone dehydrogenase or the mutant thereof, a vector for expressing the L-pantoic acid lactone dehydrogenase or the mutant thereof in a host cell, and an engineered bacterium expressing the enzyme or the mutant thereof. The present application further provides an engineered bacterium co-expressing the L-pantoic acid lactone dehydrogenase or the mutant thereof and any one or more selected from the group consisting of a chaperone, a D-ketopantoic acid lactone reductase, and a glucose dehydrogenase. The present application further provides a method for producing D-pantoic acid lactone using the engineered bacterium expressing the L-pantoic acid lactone dehydrogenase derived from Rhodococcus erythropolis or the mutant thereof.